Delivery Order SPE2DR25D2014-SPE2DR26FZ65W
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a ceiling value of $1,867.39. This firm fixed-price delivery order has an ultimate completion date of October 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded among...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $28,009.13 and is scheduled for completion by September 10, 2025. The contract represents a single line item fulfillment under AmerisourceBergen's existing pharmaceutical supply vehicle with DLA, with performance to occur...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) with a ceiling value of $3,567.44. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through competitive procurement. The order is scheduled for completion by September 29, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $6,949.42 delivery order to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on October 24, 2025, with an ultimate completion date of October 27, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price terms and is classified as a delivery order, indicating it is issued against a larger indefinite delivery vehicle. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a contract ceiling value of $7,054.75. This is a firm fixed price, non-set-aside delivery order with a completion date of September 11, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-day supply, with a ceiling value of $6,402.24. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The contract has an ultimate completion date of September 15, 2025, with performance at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) valued at $9,377.10. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement for pharmaceutical supplies supporting military and federal healthcare systems. The contract requires completion by September 18, 2025, with performance at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) with a ceiling value of $11,133.20. The contract, which is a firm fixed-price delivery order without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. This pharmaceutical supply order will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $4,560.68 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count units) on October 31, 2025, with an ultimate completion date of November 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $2,851.36 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price contract is categorized as a delivery order with an ultimate completion date of September 17, 2025, and carries no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ65WDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on November 7, 2025, with a ceiling value of $2,935.01 and completion date of November 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction supporting the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of medical product deliveries to support military and veteran healthcare systems, including medications across multiple therapeutic domains. The company's established position as a primary pharmaceutical vendor enables it to fulfill federal medical procurement requirements for defense health organizations including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 11/7/25 |